Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy.

Journal of medical virology - 1 Sept 2008

Ulasov Ilya V, Tyler Matthew A, Rivera Angel A, Nettlebeck Dirk M, Douglas Joanne T, Lesniak Maciej S

Abstract excerpt

Malignant glioma, in particular glioblastoma multiforme (GBM), represents one of the most devastating cancers currently known and existing treatment regimens do little to change patient prognosis. Conditionally replicating adenoviral vectors (CRAds) represent attractive experimental anti-cancer agents with potential for clinical application. However, early protein products of the wild type adenovirus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Adenovirus E1A Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Genetic Vectors

Share to Glioma

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Share to Virus Replication

Source

Open in PubMed Open full text

Identifiers

PMID: 18649343
DOI: 10.1002/jmv.21264
PMCID: PMC2365750

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy.PMID 18649343Read ↗

E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.Semantic proximity Read ↗

Replicative Oncolytic Adenoviruses in Multimodal Cancer RegimensSemantic proximity Read ↗

Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.Semantic proximity Read ↗

Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses.Semantic proximity Read ↗

Virus-Based Therapies for the Treatment of Recurrent High-Grade GliomaSemantic proximity Read ↗

Triple-Targeted Oncolytic Adenoviruses Featuring the Cox2 Promoter, E1A Transcomplementation, and Serotype Chimerism for Enhanced Selectivity for Ovarian Cancer CellsSemantic proximity Read ↗

Oncolytic adenoviral therapy for glioblastoma multiformeSemantic proximity Read ↗

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.Semantic proximity Read ↗

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacySemantic proximity Read ↗

Current Developments In Adenovirus-Based Cancer Gene TherapySemantic proximity Read ↗

Oncolytic Virus Therapy for Glioblastoma MultiformeSemantic proximity Read ↗

Modified adenoviruses for cancer gene therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.